📰 Solid Biosciences News
Page 12 - Solid Biosciences News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Solid Biosciences. Real-time updates on events, politics, business and more.
July 10, 2022
Pfizer has a pipeline with more than 90 drugs in development. Pfizer is developing two drugs capable of generating more than a billion sales. Competition is fierce but Pfizer is in the race.
June 30, 2022
/PRNewswire/ -- Parent Project Muscular Dystrophy (PPMD), a nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne), announced...
June 26, 2022
A Duchenne muscular dystrophy drug candidate from Italfarmaco Group has encouraging preliminary data from a pivotal study. The Milan, Italy-based pharmaceutical company says it now plans to meet with U.S. and European authorities about seeking regulatory approval for the small molecule.
May 16, 2022
A number of firms have modified their ratings and price targets on shares of Solid Biosciences (NASDAQ: SLDB) recently: 5/3/2022 – Solid Biosciences was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Solid Biosciences LLC is a life science company. It focuses on developing therapies […]
May 7, 2022
Equities analysts predict that Solid Biosciences Inc. (NASDAQ:SLDB – Get Rating) will report earnings of ($0.21) per share for the current fiscal quarter, Zacks Investment Research reports. Three analysts have issued estimates for Solid Biosciences’ earnings, with the lowest EPS estimate coming in at ($0.23) and the highest estimate coming in at ($0.17). Solid Biosciences […]
April 29, 2022
Welcome to this week's Chutes & Ladders, our ro
April 27, 2022
Solid Biosciences is cutting over a third of its workforce—for the second time in two years.
April 5, 2022
This randomized clinical trial compares the efficacy and adverse effects of the 3 most frequently prescribed corticosteroid regimens for boys with Duchenne musc